Comparative Pharmacology
Head-to-head clinical analysis: AVYCAZ versus CEDAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVYCAZ versus CEDAX.
AVYCAZ vs CEDAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AVYCAZ is a combination of ceftazidime, a cephalosporin beta-lactam antibiotic, and avibactam, a non-beta-lactam beta-lactamase inhibitor. Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis. Avibactam protects ceftazidime from degradation by certain beta-lactamases, including Ambler class A, class C, and some class D enzymes.
Ceftibuten is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP 3, thereby inhibiting peptidoglycan cross-linking and leading to cell lysis.
1 vial (ceftazidime 2g and avibactam 0.5g) IV over 2 hours every 8 hours.
400 mg orally once daily for 5-10 days.
None Documented
None Documented
Ceftazidime: ~2.8 hours; avibactam: ~2.7 hours. Extended in renal impairment (e.g., CrCl <50 mL/min requires dose adjustment).
Terminal elimination half-life: 2.6-3.0 hours; prolonged in renal impairment (up to 10-15 hours in severe impairment)
Ceftazidime: primarily renal (80-90% unchanged); avibactam: primarily renal (85-95% unchanged). Fecal excretion <1%.
Renal: 92-96% unchanged; biliary/fecal: <5%
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic